

RD General Agenda Topics – March 25, 2021

Briefings for Michal

- PRIA/registration overview 2/23rd (complete)
- Dicamba 2/18th (complete)
- Sulfoxaflor 3/4th (complete)
- Pet incidents 3/31st
- FDA/EPA jurisdiction 4/5th
- Antibiotics – TBD

New Active Ingredients (include original PRIA date)

- Tetraniliprole – completed!
- Broflanilide – completed!
- Fluindapyr – PD signed. PRIA Date **3/5/21** (Original PRIA date 5/29/20) (FB)
- Trifludimoxazin – PD signed. PRIA date **4/21/21** (Original PRIA date 10/16/2020) (FHB)
- Picarbutrazox – completed!
- Fluxametamide – completed!
- L-Glufosinate Ammonium – Risk Assessment phase. PRIA date 10/12/2021. ESA issue. Any feedback?

Other Chemical Actions

- -
 -
 -
 -
 -
 -
- ## Ex. 5 Deliberative Process (DP)

Other Actions - AA-Level/OD/High Visibility Items

- FDA/EPA jurisdiction – follow up briefing for Ed 3/10th – RD sent an email for Solomon; anything else needed?
- COVID-19 Activities – Sect 18s –

Ex. 5 Deliberative Process (DP)

- OIG Audits

Ex. 5 Deliberative Process (DP)

- PFAS – RD working with Clark on submissions

Ex. 5 Deliberative Process (DP)

- Inerts meeting with CLA
- FLS/FLAG: debuted Performance Management Toolkit for Federal Supervisors last week; interest from other AA/Regional FLAG reps in sharing it with their supervisors

Business/process/technology

- ISB – FEP/21-day backlog:
 - backlog addressed by end of April; RD SWAT team addressing newer receipts
 - **Michal feedback on expediting all covid actions? Any updates?**
- eCSF/OPPEL – OPP priority – ITRMD report May soft launch; requesting time at an OPP staff meeting

Speaking Engagements –

People/Personnel/Resources

Ex. 6 Personal Privacy (PP)

- **Ex. 6 Personal Privacy (PP)**

CA topics (Karen Morrison):

- **Ex. 5 Deliberative Process (DP)**